Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 4/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
| ▸ | CCNH | P51946 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1548065 | 0.80 | ALDH1A1 (0.40) | ALDH1A1MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL8477444 | 0.76 | DAO (0.46) | ALDH1A1MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL1523258 | 0.74 | CA2 (0.42) | ALDH1A1MAPTKDM4EMEN1LMNA | |
| SCHEMBL14077463 | 0.73 | ALDH1A1 (0.35) | ALDH1A1MAPTSMN1; SMN2KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL3869152 | 0.72 | CA2 (0.41) | ALDH1A1MAPTKDM4EMEN1LMNA | |
| SCHEMBL5183091 | 0.71 | ALDH1A1 (0.38) | NSD2ALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL8473834 | 0.69 | GAA (0.36) | ALDH1A1HPGD | |
| SCHEMBL10616070 | 0.69 | NSD2 (0.46) | NSD2ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL1548082 | 0.68 | ALDH1A1 (0.47) | NSD2ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL1523222 | 0.67 | ALDH1A1 (0.54) | ALDH1A1MAPTSMN1; SMN2MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448545-B1 | NF-KB INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-19 | — | — | EP | disclosed |
| US-7425552-B2 | Antiviral agent especially to treat hepatitis C virus infections; 5-Hydroxy-4-(7-methoxy-1,1-dioxo-1,2-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-2-(3-methyl-butyl)-6-thiophen-2-yl-2H-py-ridazin-3-one; side effects reduction | ANADYS PHARMACEUTICALS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425552-B2 | Antiviral agent especially to treat hepatitis C virus infections; 5-Hydroxy-4-(7-methoxy-1,1-dioxo-1,2-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-2-(3-methyl-butyl)-6-thiophen-2-yl-2H-py-ridazin-3-one; side effects reduction | ANADYS PHARMACEUTICALS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7166639-B2 | NF-κB inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166639-B2 | NF-κB inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166639-B2 | NF-κB inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1448545-A4 | NF-KB INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040192943-A1 | Nf-kappab inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-09-30 | — | — | US | disclosed |
| EP-1448545-A1 | NF-KB INHIBITORS | SmithKline Beecham Corporation (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003029242-A1 | NF-λB INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
| US-5889002-A | CENTRAL NERVOUS SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS; RESPIRATORY SYSTEM DISORDERS; GASTROINTESTINAL DISORDERS; ENDOCRINAL DISEASES | NOVO NORDISK A/S (DK) | 1999-03-30 | — | — | US | disclosed |
| EP-0876379-A1 | FUSED 1,2,4-THIADIAZINE AND FUSED 1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997026265-A1 | FUSED 1,2,4-THIADIAZINE AND FUSED 1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192943-A1 | Nf-kappab inhibitors | NFKBIA, IKBKB, IKBKG | NSD2 3564/4885ALDH1A1 3660/4885MAPT 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.